Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Aligos Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- −5 vs. Q1 2023
- Shares held
- 26.3M
- −1.00M (−3.7%) vs. Q1 2023
- Total value
- $25.5M
- +$1.62M (+6.8%) vs. Q1 2023
- New holders
- 3
- 5 more added
- Sold out
- 8
- 13 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALGS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $13.2M |
| Q1 2026 | 35 | $20.6M |
| Q4 2025 | 41 | $26.2M |
| Q3 2025 | 33 | $26.0M |
| Q2 2025 | 37 | $19.5M |
| Q1 2025 | 35 | $27.1M |
| Q4 2024 | 34 | $64.5M |
| Q3 2024 | 27 | $14.7M |
| Q2 2024 | 49 | $16.6M |
| Q1 2024 | 49 | $45.3M |
| Q4 2023 | 40 | $30.1M |
| Q3 2023 | 36 | $19.2M |
| Q2 2023 | 41 | $25.5M |
| Q1 2023 | 46 | $23.9M |
| Q4 2022 | 39 | $25.3M |
| Q3 2022 | 52 | $30.4M |
| Q2 2022 | 60 | $36.0M |
| Q1 2022 | 76 | $68.4M |
| Q4 2021 | 71 | $390.4M |
| Q3 2021 | 68 | $483.9M |
| Q2 2021 | 58 | $550.5M |
| Q1 2021 | 52 | $612.4M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Aligos Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Newbridge Financial Services Group, Inc. | 37 | $36 | 0.00% | 00.0% | Unchanged |
| ZRC Wealth Management, LLC | 100 | $98 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 113 | $110 | 0.00% | −2,216−95.1% | Reduced |
| Wells Fargo & Company | 198 | $192 | 0.00% | +22+12.5% | Added |
| JPMorgan Chase & Co | 677 | $657 | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 1,189 | $1.00K | 0.00% | −390−24.7% | Reduced |
| FMR LLC | 1,200 | $1.17K | 0.00% | +200+20.0% | Added |
| Federated Hermes, Inc. | 1,623 | $1.58K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 3,000 | $2.91K | 0.00% | −129,724−97.7% | Reduced |
| Advisor Group Holdings, Inc. | 8,000 | $7.77K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 10,105 | $9.00K | 0.00% | −16,168−61.5% | Reduced |
| CWM, LLC | 16,891 | $16.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 18,353 | $18.0K | 0.00% | +18,353 | New |
| HarbourVest Partners LLC | 18,783 | $18.2K | 0.01% | 00.0% | Unchanged |
| Choate Investment Advisors | 24,000 | $23.3K | 0.00% | +24,000 | New |
| Citadel Advisors LLC | 27,859 | $27.1K | 0.00% | −60,018−68.3% | Reduced |
| Two Sigma Investments, LP | 29,183 | $28.3K | 0.00% | −27,674−48.7% | Reduced |
| Charles Schwab Investment Management Inc | 31,383 | $30.5K | 0.00% | +31,383 | New |
| Northern Trust Corp | 39,351 | $38.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 52,400 | $50.9K | 0.00% | −25,800−33.0% | Reduced |
| Deutsche Bank AG | 71,290 | $69.2K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 92,000 | $89.3K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 97,423 | $94.6K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 175,875 | $170.8K | 0.00% | −227,495−56.4% | Reduced |
| Geode Capital Management, LLC | 256,592 | $249.2K | 0.00% | +56,734+28.4% | Added |
| BlackRock Inc. | 300,463 | $291.7K | 0.00% | −7,138−2.3% | Reduced |
| Renaissance Technologies LLC | 430,555 | $418.0K | 0.00% | −22,305−4.9% | Reduced |
| Acadian Asset Management LLC | 564,715 | $547.0K | 0.00% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 631,887 | $613.6K | 0.21% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $721.7K | 0.24% | 00.0% | Unchanged |
| Royal Bank of Canada | 840,393 | $816.0K | 0.00% | +795,678+1,779.4% | Added |
| Newtyn Management, LLC | 900,000 | $873.9K | 0.21% | −121,461−11.9% | Reduced |
| Vanguard Group Inc | 994,712 | $965.9K | 0.00% | −21,969−2.2% | Reduced |
| Bank of America Corp | 1,150,945 | $1.12M | 0.00% | +3,162+0.3% | Added |
| Adage Capital Partners GP, L.L.C. | 1,223,278 | $1.19M | 0.00% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 2,076,400 | $2.02M | 0.01% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 2,309,764 | $2.24M | 0.05% | 00.0% | Unchanged |
| Versant Venture Management, LLC | 2,320,381 | $2.25M | 2.67% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,329,048 | $3.23M | 0.48% | −95,752−2.8% | Reduced |
| Vivo Capital, LLC | 3,547,030 | $3.44M | 0.41% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 3,948,360 | $3.83M | 0.10% | 00.0% | Unchanged |
| Logos Global Management LP | 0 | $0 | 0.00% | −1,000,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −108,588−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −26,249−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −24,594−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −13,292−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −247−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −92−100.0% | Sold out |